cancer. However, in ADT-R CaP (androgen deprivation therapy -recurrent prostate cancer), is predominantly lethal with limited alternative therapeutic strategies 7 .
In late stage and ADT-R CaP aberrant co-repressor actions preclude NR activation, impairing anti-proliferative capacity and further epigenetic mechanisms contribute to this resistance 8 with similar events disrupting AR signaling 9, 10 (reviewed in 11 ). Specifically, PPARg actions are epigenetically disrupted and can be targeted selectively by using HDAC inhibitor cotreatments 12, 13 . Elevated levels of the co-repressors NCOR1, and to a lesser extent NCOR2/SMRT, correlated with, and functionally drive, the selective insensitivity of PPARa/g receptors towards dietary derived and therapeutic ligands 13, 14 .
One approach to target NR signaling in CaP is to target the enzymes that regulate ligand availability. Aldoketoreductase 1C3 (AKR1C3) is a multifunctional enzyme and acts as a type 2 3-alpha-Hydroxysteroid dehydrogenase or 17-beta-HSD type 5. A key regulator of steroidal metabolism, it is implicated in cancer progression. For example, silencing of AKR1C3 has been shown to inhibit cervical cancer metastasis 15 . In CaP, AKR1C3 actions are implicated in the generation of androgens [16] [17] [18] [19] , AR activation and has been investigated as a potential biomarker for in other cancer models to induce apoptosis and cell cycle arrest through PPARg driven activation pathways 34 , and other studies have echoed this approach in CaP 35 .
Therefore, the current study, examined the possibility that an AR-independent mechanism for AKR1C3 was operating in CaP cells and, in particular, we focused on a potential role in ADT-R 38 and those in classes 4-9 included known direct target genes for nuclear receptors [39] [40] [41] [42] [43] [44] [45] [46] . Total mRNA from cellcycle sorted cells was quantified in triplicate samples measured in duplicate as described Statistical analysis. Data shown are mean ± SEM of at least three independent experiments with statistical significance defined as P <0.05 (*P < 0.05; **P < 0.01; ***P < 0.001) using unpaired Students T-test and were conducted with Prism (GraphPad, CA). Statistical analysis on real-time PCR data was performed on mean dct values. There was a significant increase in AKR1C3 levels (2.69 ± 1.7 SEM). PPARA and PPARG levels were comparable between normal and tumor samples 48 . cancer prognosis [51] [52] [53] . This increase of NFKB in response to shAKR1C3 is of particular interest as it is a key driver of prostate cell proliferation and AKR1C3 presence influencing NFkB activity (through PGF2 production) has also been suggested by others 54 .
Results

AKR1C3 expression is elevated in prostate cancer
Neither
Discussion
The current study was undertaken to investigate the roles of AKR1C3 in CaP, as this enzyme is increasingly a focus in CaP research that includes its altered expression and function. The studies of others have focused on the role of this enzyme to alter ligand availability for steroidogenic androgen and estrogen receptors in the prostate. Additionally, studies and have considered the impact of PGD2 on cell proliferation in cells that over-express AKR1C3 [55] [56] [57] [58] [59] . This study investigated AKR1C3 function by undertaking knock-down and chemical inhibition approaches in parallel to compare findings to previously published over-expression approaches 56, 57 . In particular an overexpression investigation of AKR1C3 in PC-3 cells found overexpression promotes proliferation 35 . However, this study found PGD2 exposure to overexpressing AKR1C2 and AKR1C3 PC-3 models significantly reduces proliferation compared to controls. However, in this study reduction of AKR1C3 in the presence of PGD2 had no impact upon proliferation. This disparity reflects the unclear interplay between AKR1C2, AKR1C3 in prostaglandin metabolism.
PC-3 and DU 145 cells are derived from ADT-R CaP cells that are insensitive to AR signaling but retain the capacity for PPAR signaling. Therefore, knockdown of AKR1C3 in these models allows a clearer examination of the role of AKR1C3 in regulating PPARg.
However, shAKR1C3 expression did not significantly alter responses to either endogenous (PGD2) or synthetic PPARg (GW9662) ligands.
These data support the concept that either AKR1C3 is not a major regulator of PPARg in prostate cells or that in CaP the ability of AKR1C3 to exert such an action is overridden by epigenetic events 36, 37, 64 . Therefore SAHA was utilized in an attempt to restore PPARg function. Interestingly, the shAKR1C3 clones of DU 145 were significantly more sensitive to SAHA than controls; in PC- cohort of 118 metastatic castrate recurrent tumors 68 . From these analyses we generated heatmaps for each of the tumor cohort (Supplementary Figure 1) . In each case AKR1C3 (red arrowhead) grouped by expression in a different cluster than the AR (Black arrowhead). In particular AKR1C3 expression clusters more closely with PPARs than the AR. These findings suggest that taking an unbiased approach to the networks in which AKR1C3 is implicated supports a role of close association with PPARs rather than the AR and this is especially evident in aggressive and advanced disease that has failed anti-androgen treatment. proteins including histone deacetylase (HDAC1), the DNA methyltransferases (DNMT1 and DNMT3B) 72 , and a number of transcription factors (NFYa and b) 73 . These findings generate confidence that a ZHX1 complex initiates chromatin condensation and leads to gene silencing. Together we believe strongly that our data generated by two different experimental approaches, and these parallel findings from others indicate a direct and functional link between AKR1C3 and the regulation of the epigenome.
The current study has revealed a novel role of AKR1C3 expression on the epigenetic status of prostate cancer cells that is independent of AR and PPARs signaling and highlights the potential for selective inhibitors of AKRIC3 in combination with SAHA or other HDAC inhibitors as prospective therapy in AR resistant disease ( Figure 5 ).
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